Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells

Vaccine

Volumn 25, Issue 14, 2007, Pages 2610-2619

  Koido, Shigeo ^b,c   Tanaka, Yasuhiro ^c   Tajiri, Hisao ^b   Gong, Jianlin ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adoptive immunotherapy; Allogeneic breast cancer cells; DC breast cancer fusion cells; SCID mice

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; HLA A2 ANTIGEN; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALTERNATIVE MEDICINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL FUSION; CELL STIMULATION; CELL STRAIN MCF 7; CELL THERAPY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE INTERVAL; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CELL FUSION; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HLA-A ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33947188082     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.035     Document Type: Article

References (31)

1. Gong J., Chen D., Kashiwaba M., and Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3 5 (1997) 558-561
2. Gong J., Avigan D., Chen D., Wu Z., Koido S., Kashiwaba M., et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97 6 (2000) 2715-2718
3. Gong J., Nikrui N., Chen D., Koido S., Wu Z., Tanaka Y., et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165 3 (2000) 1705-1711
4. Kikuchi T., Akasaki Y., Irie M., Homma S., Abe T., and Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50 7 (2001) 337-344
5. Krause S.W., Neumann C., Soruri A., Mayer S., Peters J.H., and Andreesen R. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 25 5 (2002) 421-428
6. Tanaka Y., Koido S., Chen D., Gendler S.J., Kufe D., and Gong J. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 101 2 (2001) 192-200
7. Galea-Lauri J., Darling D., Mufti G., Harrison P., and Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51 6 (2002) 299-310
8. Marten A., Renoth S., Heinicke T., Albers P., Pauli A., Mey U., et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 14 5 (2003) 483-494
9. Fabre J.W. The allogeneic response and tumor immunity. Nat Med 7 6 (2001) 649-652
10. Koido S., Kashiwaba M., Chen D., Gendler S., Kufe D., and Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165 10 (2000) 5713-5719
11. Rosenberg S.A., Spiess P., and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233 4770 (1986) 1318-1321
12. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319 25 (1988) 1676-1680
13. Itoh K., Platsoucas C.D., and Balch C.M. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 168 4 (1988) 1419-1441
14. Prevost-Blondel A., Zimmermann C., Stemmer C., Kulmburg P., Rosenthal F.M., and Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 161 5 (1998) 2187-2194
15. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86 15 (1994) 1159-1166
16. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 23 (1985) 1485-1492
17. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 5594 (2002) 850-854
18. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 10 (2005) 2346-2357
19. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18 4 (1997) 175-182
20. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99 25 (2002) 16168-16173
21. Baskar S., Glimcher L., Nabavi N., Jones R.T., and Ostrand-Rosenberg S. Major histocompatibility complex class II + B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181 2 (1995) 619-629
22. Young J.W., and Steinman R.M. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J Exp Med 171 4 (1990) 1315-1332
23. Gong J., Apostolopoulos V., Chen D., Chen H., Koido S., Gendler S.J., et al. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 101 3 (2000) 316-324
24. Apostolopoulos V., Loveland B.E., Pietersz G.A., and McKenzie I.F. CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol 155 11 (1995) 5089-5094
25. Acres B., Apostolopoulos V., Balloul J.M., Wreschner D., Xing P.X., Ali-Hadji D., et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48 10 (2000) 588-594
26. Jerome K.R., Barnd D.L., Bendt K.M., Boyer C.M., Taylor-Papadimitriou J., McKenzie I.F., et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51 11 (1991) 2908-2916
27. Barnd D.L., Lan M.S., Metzgar R.S., and Finn O.J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86 18 (1989) 7159-7163
28. Domenech N., Henderson R.A., and Finn O.J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155 10 (1995) 4766-4774
29. Apostolopoulos V., Karanikas V., Haurum J.S., and McKenzie I.F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159 11 (1997) 5211-5218
30. Agrawal B., Reddish M.A., and Longenecker B.M. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157 5 (1996) 2089-2095
31. Koido S., Tanaka Y., Chen D., Kufe D., and Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol 168 5 (2002) 2111-2117